Current tumor targeting strategies for therapy are largely based on differentiation antigens, such as prostate specific antigen and androgen receptor, but our previous studies have shown that the cells that self-renew are a population of primitive cells with the phenotype α2β1hi/CD133+, which are most likely unaffected by current chemotherapeutic regimes [4]. Here, AR is linked to neoplasm.